Venture targets specialty drugs" /> Venture targets specialty drugs | Chemical & Engineering News
Volume 84 Issue 21 | p. 19 | Concentrates
Issue Date: May 22, 2006

Venture targets specialty drugs

Department: Business

Vectura Group and Unilever Ventures have spun off portions of their technology platforms to form the specialty pharmaceutical company PharmaKodex. The new firm will develop drugs by repurposing existing drugs for new indications or by improving the way they are administered. Vectura is contributing oral and dermal technologies; Unilever Ventures is contributing a particle formulation/solubilization nanotechnology from Iota NanoSolutions, another Unilever spin-off, and encapsulation technology from its parent, Unilever PLC.

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society